Research output per year
Research output per year
Search results
-
2022
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)
van Breeschoten, J., Wouters, M. W. J. M., Hilarius, D. L., Haanen, J. B., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J-W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Blokx, W. A. M., Tije, B-J. J. T., Veldt, A. A. M. V. D., Vreugdenhil, A., Boers-Sonderen, M. J. & van den Eertwegh, A. J. M., 18 May 2022, In: British Journal of Cancer. 126, 9, p. 1362 1 p.Research output: Contribution to journal › Comment/Letter to the editor › Academic
Open Access -
2021
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1): First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)
van Breeschoten, J., Wouters, M. W. J. M., Hilarius, D. L., Haanen, J. B., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J-W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Blokx, W. A. M., ten Tije, B-J. J., van der Veldt, A. A. M., Vreugdenhil, A., Boers-Sonderen, M. J. & van den Eertwegh, A. J. M., 11 May 2021, In: British Journal of Cancer. 124, 10, p. 1746 1 p.Research output: Contribution to journal › Comment/Letter to the editor › Academic